Connect Biopharma Holdings Ltd (NASDAQ:CNTB)
| Market Cap | $38.05M-79.7% |
| Revenue (ttm) | $2.77M-88.7% |
| Net Income | -$33.43M-9.2% |
| EPS | -$0.53+24.3% |
| Shares Out | 64.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 365,982 |
| Open | $0.64 |
| Previous Close | $0.63 |
| Day's Range | $0.59 - $0.64 |
| 52-Week Range | $0.55 - $3.82 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $7.25(+1128.81%) |
| Earnings Date | Mar 30, 2027 |
About CNTB
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating CNTB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 30, 2027Earnings report
$CNTB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in CNTB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CNTB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CNTB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CNTB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CNTB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CNTB
| IWMiShares Russell 2000 ETF | $233.04K |
| IWOiShares Russell 2000 Growth ETF | $72.59K |
| VTWOVanguard Russell 2000 ETF | $69.86K |
| IWNiShares Russell 2000 Value ETF | $67.29K |
| IWCiShares Micro-Cap ETF | $26.64K |
| VTWGVanguard Russell 2000 Growth ETF | $7.92K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CNTB’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
